Abstract:
Diagnosis and treatment of chronic coronary heart disease (CHD) is well developed, but there
are often difficulties in managing patients with comorbid diseases. A very common chronic kidney
disease (CKD) occupies a special place among comorbidities. The cause of death in patients with
kidney dysfunction is significantly more often CHD than end-stage renal disease (ESRD). In recent
years, cystatin C has been considered as an early marker for assessing the functional state of the
kidneys and cardiovascular risk, the level of which, unlike creatinine, does not depend on gender,
age, race, and muscle mass.
